International Mesothelioma Conference Will Kick Off at UCLA
Thoracic surgeon and renowned mesothelioma specialist Dr. Robert Cameron will be hosting the 6th International Symposium on Malignant Pleural Mesothelioma on Saturday, Sept. 24, at the UCLA School of Medicine. Cameron, director of the UCLA Comprehensive Mesothelioma Program, is a global leader in the development of the lung-sparing pleurectomy/decortication surgery and a vocal advocate for military veterans who develop the asbestos-related disease. The conference will cover the latest in mesothelioma therapeutics, including novel immunotherapies, gene therapy, upcoming clinical trials and surgical advancements. The purpose is to improve the understanding of multidisciplinary treatment, learn about adjuvant therapy possibilities, raise awareness to various types of immunological therapies, and emphasize the need to treat mesothelioma as a chronic disease. Oncologists, pulmonologists, surgeons, nurses, medical students, mesothelioma advocates, patients and families across the nation will attend to exchange thoughts and ideas. The Mesothelioma Center’s Patient Advocates Karen Selby and Vanessa Blanco will participate, ensuring patients and loved ones who reach out to the organization in the coming months will receive the latest information on mesothelioma treatments. Selby, a registered nurse with a surgical and oncological background, joined The Mesothelioma Center in 2009. “It’s important for us to be there, hearing about the cutting-edge research and learni...
CONCLUSIONS: Although jobs with high potential for exposure to asbestos products were held by only 20% of the enlisted naval population, sailors with these jobs (machinist's mate, pipe fitter, boiler technician, water tender and fireman) experienced 55% of mesothelioma deaths. The significantly higher mortality rate overall was explained by asbestos exposure among enlisted naval personnel in this low-dose radiation exposed cohort. PMID: 30513236 [PubMed - as supplied by publisher]
You're reading 4 Key Ingredients to Avoid in Cosmetics, originally posted on Pick the Brain | Motivation and Self Improvement. If you're enjoying this, please visit our site for more inspirational articles. As you walk down a store’s beauty aisle, it’s easy to choose the most popular brands and products that line the shelves. After all, they are on sale and the labels claim to be organic or all natural. Despite these perks, what consumers fail to realize is that these labels can deceive consumers into believing their items are safe and toxin-free. The truth is the beauty market across the United States has lack...
Malignant pleural mesothelioma (MPM) remains a devastating disease with an increasing worldwide incidence. Prognosis is poor; median overall survival is only 9-18 months. Few patients are suitable for surgery and the mainstay of therapy remains systemic cytotoxic chemotherapy. Combination cisplatin/pemetrexed is the standard of care first line regimen, offering survival benefit of a few months. Patients invariably progress, and while there is currently no established second line regimen, single agent vinorelbine is used on the basis of activity in small trials.
Radiation oncologist Dr. Andrea McKee believes deaths from lung cancer — including those related to asbestos exposure — could be reduced significantly by increased utilization of early CT screening. McKee, chair of radiation oncology at Lahey Hospital and Medical Center in Burlington, Maine, has been a strong proponent of early screening for several years. “We could be saving tens of thousands of lives every year with this,” McKee told The Mesothelioma Center at Asbestos.com. “There is nothing else like it. The life-saving potential is the most important thing that has happened to cancer in my...
Conclusions: Forty years after the Occupational and Safety Health Act, mesothelioma incidence and mortality remain elevated in Wisconsin, with increased risk continuing for certain I&O groups.
Condition: Mesotheliomas Pleural Interventions: Drug: Pembrolizumab; Procedure: Indocyanine Green (ICG) Image-Guided Surgery; Drug: Cisplatin; Drug: Pemetrexed Sponsor: Abramson Cancer Center of the University of Pennsylvania Not yet recruiting
This article is protected by copyright. All rights reserved.
Malignant mesothelioma is associated with long-term exposure to asbestos [1 –3]. Consequently, asbestos consumption is banned or controlled in a large number of industrialized countries and should be banned worldwide to reduce the incidence of asbestos-related diseases [4–6]. However, the incidence of mesothelioma continues to go up due to the long latency period of 20- 50 years between exposure and the development of mesothelioma [7,8].
The biennial conference of the International Mesothelioma Interest Group (iMig) includes a dedicated imaging session that features recent advances in imaging research and clinical adaptation of imaging technology in the diagnosis and evaluation of mesothelioma [1 –5]. Imaging continues to play a critical role in the evaluation and surveillance of malignant pleural mesothelioma (MPM) patients, and researchers continue to seek ways to enhance, optimize, and extend the many roles that imaging has in the MPM setting.
Treatment options for malignant mesothelioma may soon include customized gene therapy, according to thoracic surgeon and scientist Dr. Prasad Adusumilli at Memorial Sloan Kettering Cancer Center in New York. Gene therapy involves a laboratory reprogramming of a patient’s own T cells, which are a type of white blood cell, to recognize and destroy the cancer. The U.S. Food and Drug Administration (FDA) recently approved the first gene therapy specifically for pediatric leukemia, signaling the start of a new approach to cancer treatment in this country. The newly approved treatment is also known as chimeric antigen rece...
More News: Allergy & Immunology | Asbestosis | Cancer | Cancer & Oncology | Cancer Therapy | Cardiology | Cardiovascular & Thoracic Surgery | Clinical Trials | Conferences | Environmental Health | Gene Therapy | Genetics | Heart | Immunotherapy | Learning | Mesothelioma | New York University | Nurses | Nursing | Students | Universities & Medical Training